By Daniel R. Matlis
In October, I had the privilege to visit Mumbai, India, to provide the keynote address at a series of Life-Science Executive Industry events on Quality and Manufacturing organized by Dassault Systèmes Biovia Corp.
This visit afforded me a great opportunity to meet with executives from many of India’s largest Life-Science companies, get a taste of Indian culture and share Axendia’s insights on trends impacting the global and externalized industry.
I also gained a new perspective on the Compliance vs Quality paradox.
During my keynote I emphasized the need for Life-Science Organizations to transition their focus from mere Compliance towards a culture driving Quality improvements across the organization.
Compliance is a Baseline, it is the cost of doing business in the Life-Sciences Industry. Collecting documented evidence of compliance with regulatory requirements is an overhead cost for Life-Science companies.
By contrast, Quality is an Investment. Improvements in quality drive enhanced and consistent product performance. In addition streamlined processes result in operational efficiencies and reduce waste. Investing in improving product quality lowers costs and improves outcomes